EMA Authorised: Gohibic (vilobelimab) — InflaRx GmbH

View source ↗

Summary

The European Medicines Agency authorised Gohibic (vilobelimab) from InflaRx GmbH for use in adults with respiratory distress syndrome and COVID-19 infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Gohibic (vilobelimab)

Snippet

Status: Authorised. Therapeutic area: Respiratory Distress Syndrome, Adult;COVID-19 virus infection. MAH: InflaRx GmbH. Decision date: 17/03/2026